We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

82 hedge funds and large institutions have $147M invested in iShares US Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 34 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

37.62% more ownership

Funds ownership: 102.5% → 140.12% (+38%)

33% more capital invested

Capital invested by funds: $111M → $147M (+$36.3M)

6% less funds holding

Funds holding: 87 → 82 (-5)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

50% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 34

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $348K

Holders
82
Holders Change
-5
Holders Change %
-5.75%
% of All Funds
1.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
17
Reduced
34
Closed
13
Calls
$1K
Puts
$348K
Net Calls
-$347K
Net Calls Change
-$349K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$57.5M
2
RCYC
Richard C. Young & Co
Rhode Island
+$3.92M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$3.47M
4
Fisher Asset Management
Fisher Asset Management
Washington
+$222K
5
Wolverine Trading
Wolverine Trading
Illinois
+$221K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$6.2M
2
BW
Biegel & Waller
Maryland
-$5.99M
3
Morgan Stanley
Morgan Stanley
New York
-$1.61M
4
Wells Fargo
Wells Fargo
California
-$1.05M
5
TRCT
Tower Research Capital (TRC)
New York
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
51
Fidelity Investments
Massachusetts
$133K -$59K -1,233 -30%
Citigroup
52
Citigroup
New York
$119K +$36.6K +765 +43%
CFGS
53
Concourse Financial Group Securities
Alabama
$114K -$28.3K -591 -19%
US Bancorp
54
US Bancorp
Minnesota
$108K – – –
SFS
55
Sowell Financial Services
Arkansas
$77K +$78.7K +1,644 New
AA
56
Advisory Alpha
Michigan
$76.6K +$79.7K +1,665 New
VFA
57
Valeo Financial Advisors
Indiana
$60K +$2.15K +45 +4%
BFC
58
Bedel Financial Consulting
Indiana
$59K – – –
AIC
59
Ameritas Investment Company
Nebraska
$56K +$57.8K +1,206 New
FANJ
60
Financial Architects (New Jersey)
New Jersey
$54K – – –
PNC Financial Services Group
61
PNC Financial Services Group
Pennsylvania
$54K +$144 +3 +0.3%
TRCT
62
Tower Research Capital (TRC)
New York
$53K -$1.01M -21,072 -95%
FCMT
63
Founders Capital Management (Texas)
Texas
$36K – – –
JHCP
64
Jackson Hole Capital Partners
Oklahoma
$35K – – –
LWM
65
Liberty Wealth Management
California
$30K -$5.6K -117 -15%
IA
66
IFP Advisors
Florida
$30K +$31.5K +657 New
GRP
67
Global Retirement Partners
California
$29K +$144 +3 +0.5%
ASN
68
Advisory Services Network
Georgia
$27K – – –
FFW
69
Fusion Family Wealth
New York
$24K – – –
GWM
70
Geneos Wealth Management
Colorado
$21K – – –
Fifth Third Bancorp
71
Fifth Third Bancorp
Ohio
$20K – – –
William Blair & Company
72
William Blair & Company
Illinois
$20K – – –
SWP
73
Strategic Wealth Partners
Ohio
$16.8K +$17.2K +360 New
RIA
74
Realta Investment Advisors
Delaware
$13K -$3.02K -63 -18%
Northwestern Mutual Wealth Management
75
Northwestern Mutual Wealth Management
Wisconsin
$11K – – –
1 2
3
4

IHE Hedge Fund Activity: Q3 2019 in Review

82 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2019, worth a combined $147M — up 33% from $111M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of IHE and 9 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 17 added.

The largest buyer was Goldman Sachs, adding an estimated $57.5M. The largest seller was Jane Street, cutting an estimated $6.2M.

  • 82 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2019, down from 87 in Q2 2019.
  • Funds reported $147M of iShares US Pharmaceuticals ETF stock for Q3 2019, up 33% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2019 and 13 closed out, a net change of -4 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2019 was Goldman Sachs, an estimated $57.5M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2019 was Jane Street, an estimated $6.2M sold.

Based on aggregated 13F filings for Q3 2019.